Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Selective Inhibition of AKT Pr...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Selective Inhibition of AKT Protein Isoforms Augments Gefitinib Response in EGFR Mutated NSCLC Cells
Bibliographic Details
Main Authors:
Bokobza, S
,
Devery, A
,
Weber, A
,
Jiang, Y
,
Ryan, A
Format:
Conference item
Published:
2012
Holdings
Description
Similar Items
Staff View
Similar Items
Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
by: Yibo Zhao, et al.
Published: (2018-06-01)
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
by: Makoto Nishio, MD, PhD, et al.
Published: (2022-04-01)
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
by: Bin Zou, et al.
Published: (2018-03-01)
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer
by: Weber, A, et al.
Published: (2016)
Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
by: Chien-Hung Gow, et al.
Published: (2005-09-01)